| Field | Specification |
|---|---|
| Target | |
| Alternative names | Echinoderm microtubule-associated protein-like 4; EMAP-4; Restrictedly overexpressed proliferation-associated protein; Ropp 120; EML4; C2orf2; EMAPL4 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E. coli-derived human EML4 recombinant protein (Position: K207-N423). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes echinoderm microtubule-associated protein-like 4 (gene EML4) in human samples and is validated for ELISA, flow cytometry, ICC/IF, IHC and Western blot. The predicted molecular weight is 108.9 kDa, and the supplier reports an observed band at about 120 kDa.
EML4 (echinoderm microtubule-associated protein-like 4) binds and stabilizes microtubules. It contributes to mitotic spindle organization and correct kinetochore attachment during cell division. EML4 is also widely known as the fusion partner in EML4-ALK rearrangements found in a subset of non-small cell lung cancers.
| Target | Echinoderm microtubule-associated protein-like 4 (gene EML4; UniProt Q9HC35, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 108.9 kDa |
| Observed MW | 120 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human HepG2 cells, human A549 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 8% SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human placenta tissue, human colorectal adenocarcinoma tissue, human esophageal squamous carcinoma tissue, human liver cancer tissue, human ovarian serous adenocarcinoma tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): human colorectal cancer tissue, human ovarian cancer tissue.
Samples with a confirmed signal (flow cytometry): A549 cells.
Immunogen
Recombinant human EML4 fragment (Lys207–Asn423), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human. UniProt places echinoderm microtubule-associated protein-like 4 in the cytoplasm and midbody. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
